A population-based study in Ghana to investigate inter-individual variation in plasma t-PA and PAI-1

Ethnicity and Disease

Volumn 17, Issue 3, 2007, Pages 492-497

  Williams, Scott M ^a,b   Stocki, Shelli ^d   Jiang, Lan ^a   Brew, Kwabena ^c   Gordon, Seth ^c   Vaughan, Douglas E ^b   Brown, Nancy J ^b   Poku, Kwabena A ^c   Moore, Jason H ^d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Regional Hospital   (Ghana)

^c UNIVERSITY OF GHANA BUSINESS SCHOOL   (Ghana)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Genetic risk; Study design; Thrombosis

Indexed keywords

CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTERY THROMBOSIS; ARTICLE; BODY MASS; CHRONIC DISEASE; DEMOGRAPHY; ENVIRONMENTAL FACTOR; FEMALE; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; GHANA; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; THROMBOGENESIS; VALIDATION PROCESS;

ADULT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GHANA; HUMANS; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SEX FACTORS; TISSUE PLASMINOGEN ACTIVATOR; VENOUS THROMBOSIS;

EID: 35349014250     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Lijnen RH, Collen D. Thrombolytic agents. Cardiovascular Thrombosis: Thrombocardiology and Thromboneurology. Philadelphia: Lippincott-Raven; 1998.
2. Souto JC, Almasy L, Borrell M, et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia. Am J Hum Genet. 2000;67:1452-1459.
3. Harker LA, Mann KG. Thrombosis and fibrinolyisis. Cardiovascular Thrombosis: Thrombocardiology and Thromboneurology. Philadelphia: Lippincott-Raven; 1998.
4. Sing CF, Moll PP. Genetics of atherosclerosis. Annu Rev Genet. 1990;24:171-187.
5. Sing CF, Stengard JH, Kardia SL. Genes, environment, and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2003;23:1190-1196.
6. Brown NJ, Nadeau JH, Vaughan DE. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost. 1997;77:522-525.
7. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension. 1998;32:965-971.
8. Brown NJ, Gainer JV, Stein CM, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension. 1999;33:1431-1435.
9. Brown NJ, Gainer JV, Murphey LJ, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation. 2000;102: 2190-2196.
10. Vaughan DE. The renin-angiotensin system and fibrinolysis. Am J Cardiol. 1997;79:12-16.
11. Burzotta F, Di Castelnuovo A, Amore C, et al. 4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: a model of gene-environment interaction. Thromb Haemost. 1998;79:354-358.
12. Margaglione M, Cappucci G, Colaizzo D, et al. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vasc Biol. 1998;18:152-156.
13. Kim DK, Kim JW, Kim S, et al. Polymorphism of angiotensin converting enzyme gene is associated with circulating levels of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol. 1997;17:3242-3247.
14. Hou RF, Tu WC, Lee HH, Chen KM, Chou HL, Lai SC. Elevation of plasminogen activators in cerebrospinal fluid of mice with eosinophilic meningitis caused by Angiostrongylus cantonensis. Int J Parasitol. 2004;34: 1355-1364.
15. Jin T, Bokarewa M, Tarkowski A. Urokinase-type plasminogen activator, an endogenous antibiotic. J Infect Dis. 2005:192:429-437.
16. Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes. 2004;53:2079-2086.
17. Shapiro SS, Wilk MB. An analysis of variance test for normality. Biometrika. 1965;52:591-611.
18. Royston JP. An extension of Shapiro and Wilks W test for normality to large samples. Applied Statistics. 1982;31:115-124.
19. Box GEP, Cox DR. An analysis of transformations. J R Stat Soc Series B. 1964;26:211-243.
20. Barnett V, Lewis T. Outliers in Statistical Data. 3rd ed edition. Chichester: Wiley & Sons; 1994.
21. Satterthwaite FW. An Approximate Distribution of Estimates of Variance Components. Biometrics Bulletin. 1946;2:110-114.
22. Bradley JV. Distribution-Free Statistical Tests. Englewood Cliffs, NJ: Prentice-Hall; 1968.
23. Steel RGD, Torrie JH. Principles and Procedures of Statistics: A Biometrical Approach. 2nd ed. New York: McGraw-Hill; 1980.
24. Peetz D, Victor A, Adams P, et al. Genetic and environmental influences on the fibrinolytic system: a twin study. Thromb Haemost. 2004;92:344-3451.
25. Adeyemo AA, Chen G, Chen Y, Rotimi C. Genetic structure in four West African population groups. BMC Genet. 2005;6:38.
26. De Taeye B, Smith LH, Vaughan DE. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol. 2005; 5:149-154.
27. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation. 2004; 109:IV6-19.
28. Abbasi F, Brown BW, Jr., Lamendola C, McLaughlin T, Reaven GM. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol. 2002;40:937-943.
29. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345:790-797.
30. Bensen JT, Hsu FC, Brown WM, et al. Association analysis of the plasminogen activator inhibitor-1 4G/5G polymorphism in Hispanics and African Americans: the IRAS family study. Hum Hered. 2004;57:128-137.
31. Festa A, D'Agostino R, Jr., Rich SS, Jenny NS, Tracy RP, Haffner SM. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Circulation. 2003;107:2422-2427.
32. Schreiner PJ, Wu KK, Malinow MR, et al. Hyperhomocyst(e)inemia and hemostatic factors: the atherosclerosis risk in communities study. Ann Epidemiol. 2002;12:228-2236.
33. Solano MP, Perry AC, Wang X, Ross R, Goldberg RB. Insulin resistance but not visceral adipose tissue is associated with plasminogen activator inhibitor type 1 levels in overweight and obese premenopausal African-American women. Int J Obes Relat Metab Disord. 2003;27:82-87.
34. Moore JH, Smolkin ME, Lamb JM, Brown NJ, Vaughan DE. The relationship between plasma t-PA and PAI-1 levels is dependent on epistatic effects of the ACE I/D and PAI-1 4G/5G polymorphisms. Clin Genet. 2002;62:53-59.
35. Wagenknecht LE, Mayer EJ, Rewers M, et al. The insulin resistance atherosclerosis study (IRAS) objectives, design, and recruitment results. Ann Epidemiol. 1995;5:464-472.
36. Bourne LT, Lambert EV, Steyn K. Where does the black population of South Africa stand on the nutrition transition? Public Health Nutr. 2002;5:157-162.
37. Barrett-Connor E. Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. Circulation. 1997;95:252-264.